FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112474489> ?p ?o ?g. }

• W2112474489 endingPage "727" @default.
• W2112474489 startingPage "717" @default.
• W2112474489 abstract "Vaccine effectiveness of pneumococcal conjugate vaccines against culture-confirmed invasive pneumococcal disease has been well documented. In the Finnish Invasive Pneumococcal disease (FinIP) trial, we reported vaccine effectiveness and absolute rate reduction against laboratory-confirmed invasive pneumococcal disease (confirmation by culture or antigen or DNA detection irrespective of serotype). Here, we assessed vaccine effectiveness of PHiD-CV10 against clinically suspected invasive pneumococcal disease in children by use of diagnoses coded in hospital discharge registers.For this phase 3/4 cluster-randomised, double-blind trial, undertaken between Feb 18, 2009, and Dec 31, 2011, in municipal health-care centres and the Tampere University Vaccine Research Centre (Finland), we randomly assigned (2:2:1:1) 78 clusters into PHiD-CV10 three plus one, PHiD-CV10 two plus one, control three plus one, control two plus one groups (26:26:13:13 clusters) to give PHiD-CV10 in either three plus one or two plus one schedule (if enrolled before 7 months of age; infant schedules), two plus one (if enrolled between 7 and 11 months; catch-up schedules), and two doses at least 6 months apart (if enrolled between 12 and 18 months; catch-up schedules). Children were eligible if they had not received and were not anticipated to receive any of the study vaccines and had no general contraindications to vaccinations. We collected all inpatient and outpatient discharge notifications from the national hospital discharge register with International Classification of Diseases (ICD) 10 diagnoses compatible with invasive pneumococcal disease or unspecified sepsis, and verified data with patient files. We excluded invasive pneumococcal disease cases confirmed by positive culture or DNA/RNA detection from normally sterile body fluid. The primary objective was to estimate vaccine effectiveness against all register-based non-laboratory-confirmed invasive pneumococcal disease or unspecified sepsis and patient-file verified non-laboratory-confirmed invasive pneumococcal disease in infants younger than 7 months at enrolment. Masked follow-up lasted from the date of the first vaccination to Dec 31, 2011. Vaccine effectiveness was calculated against all episodes. This trial is registered with ClinicalTrials.gov, numbers NCT00861380 and NCT00839254.We enrolled 47,366 children. On the basis of ICD-10 diagnoses, we recorded 264 episodes of register-based non-laboratory-confirmed invasive pneumococcal disease or unspecified sepsis, of which 102 were patient-file verified non-laboratory-confirmed invasive pneumococcal disease. The vaccine effectiveness was 50% (95% CI 32-63) in the 30,527 infants with three plus one and two plus one schedules combined and the absolute incidence rate reduction was 207 episodes per 100,000 person-years (95% CI 127-286). The vaccine effectiveness against the patient-file verified non-laboratory-confirmed invasive pneumococcal disease was 71% (95% CI 52-83) in infant three plus one and two plus one schedules combined. The absolute rate reduction was 142 episodes per 100,000 person-years (95% CI 91-191) in infant cohorts.This vaccine-probe analysis is the first report showing the effect of pneumococcal conjugate vaccines on clinically suspected invasive pneumococcal disease. The absolute rate reduction was markedly higher compared with laboratory-confirmed invasive pneumococcal disease, which implies low sensitivity of the laboratory-based case definitions and subsequently higher public health effect of pneumococcal conjugate vaccines against invasive pneumococcal disease than previously estimated.GlaxoSmithKline Biologicals SA and National Institute for Health and Welfare (THL), Finland." @default.
• W2112474489 created "2016-06-24" @default.
• W2112474489 creator A5001153276 @default.
• W2112474489 creator A5006068743 @default.
• W2112474489 creator A5011179705 @default.
• W2112474489 creator A5013703830 @default.
• W2112474489 creator A5038579099 @default.
• W2112474489 creator A5044909063 @default.
• W2112474489 creator A5057270816 @default.
• W2112474489 creator A5058854963 @default.
• W2112474489 creator A5072697665 @default.
• W2112474489 creator A5074159991 @default.
• W2112474489 date "2014-09-01" @default.
• W2112474489 modified "2023-09-25" @default.
• W2112474489 title "Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial" @default.
• W2112474489 cites W1967560302 @default.
• W2112474489 cites W1970041510 @default.
• W2112474489 cites W1984046165 @default.
• W2112474489 cites W2004505189 @default.
• W2112474489 cites W2023690749 @default.
• W2112474489 cites W2074074587 @default.
• W2112474489 cites W2092915795 @default.
• W2112474489 cites W2093536091 @default.
• W2112474489 cites W2093931806 @default.
• W2112474489 cites W2103637444 @default.
• W2112474489 cites W2115456658 @default.
• W2112474489 cites W2122264420 @default.
• W2112474489 cites W2130300971 @default.
• W2112474489 cites W2136544583 @default.
• W2112474489 cites W2137828128 @default.
• W2112474489 cites W2149008929 @default.
• W2112474489 cites W2149176649 @default.
• W2112474489 cites W2170396769 @default.
• W2112474489 cites W2171651817 @default.
• W2112474489 doi "https://doi.org/10.1016/s2213-2600(14)70139-0" @default.
• W2112474489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25127244" @default.
• W2112474489 hasPublicationYear "2014" @default.
• W2112474489 type Work @default.
• W2112474489 sameAs 2112474489 @default.
• W2112474489 citedByCount "42" @default.
• W2112474489 countsByYear W21124744892014 @default.
• W2112474489 countsByYear W21124744892015 @default.
• W2112474489 countsByYear W21124744892016 @default.
• W2112474489 countsByYear W21124744892017 @default.
• W2112474489 countsByYear W21124744892018 @default.
• W2112474489 countsByYear W21124744892019 @default.
• W2112474489 countsByYear W21124744892020 @default.
• W2112474489 countsByYear W21124744892021 @default.
• W2112474489 countsByYear W21124744892022 @default.
• W2112474489 countsByYear W21124744892023 @default.
• W2112474489 crossrefType "journal-article" @default.
• W2112474489 hasAuthorship W2112474489A5001153276 @default.
• W2112474489 hasAuthorship W2112474489A5006068743 @default.
• W2112474489 hasAuthorship W2112474489A5011179705 @default.
• W2112474489 hasAuthorship W2112474489A5013703830 @default.
• W2112474489 hasAuthorship W2112474489A5038579099 @default.
• W2112474489 hasAuthorship W2112474489A5044909063 @default.
• W2112474489 hasAuthorship W2112474489A5057270816 @default.
• W2112474489 hasAuthorship W2112474489A5058854963 @default.
• W2112474489 hasAuthorship W2112474489A5072697665 @default.
• W2112474489 hasAuthorship W2112474489A5074159991 @default.
• W2112474489 hasBestOaLocation W21124744892 @default.
• W2112474489 hasConcept C126322002 @default.
• W2112474489 hasConcept C168563851 @default.
• W2112474489 hasConcept C176400912 @default.
• W2112474489 hasConcept C187212893 @default.
• W2112474489 hasConcept C203014093 @default.
• W2112474489 hasConcept C22070199 @default.
• W2112474489 hasConcept C2776925733 @default.
• W2112474489 hasConcept C2778866548 @default.
• W2112474489 hasConcept C2779301066 @default.
• W2112474489 hasConcept C2781253189 @default.
• W2112474489 hasConcept C523546767 @default.
• W2112474489 hasConcept C54355233 @default.
• W2112474489 hasConcept C71924100 @default.
• W2112474489 hasConcept C86803240 @default.
• W2112474489 hasConceptScore W2112474489C126322002 @default.
• W2112474489 hasConceptScore W2112474489C168563851 @default.
• W2112474489 hasConceptScore W2112474489C176400912 @default.
• W2112474489 hasConceptScore W2112474489C187212893 @default.
• W2112474489 hasConceptScore W2112474489C203014093 @default.
• W2112474489 hasConceptScore W2112474489C22070199 @default.
• W2112474489 hasConceptScore W2112474489C2776925733 @default.
• W2112474489 hasConceptScore W2112474489C2778866548 @default.
• W2112474489 hasConceptScore W2112474489C2779301066 @default.
• W2112474489 hasConceptScore W2112474489C2781253189 @default.
• W2112474489 hasConceptScore W2112474489C523546767 @default.
• W2112474489 hasConceptScore W2112474489C54355233 @default.
• W2112474489 hasConceptScore W2112474489C71924100 @default.
• W2112474489 hasConceptScore W2112474489C86803240 @default.
• W2112474489 hasIssue "9" @default.
• W2112474489 hasLocation W21124744891 @default.
• W2112474489 hasLocation W21124744892 @default.
• W2112474489 hasLocation W21124744893 @default.
• W2112474489 hasOpenAccess W2112474489 @default.
• W2112474489 hasPrimaryLocation W21124744891 @default.
• W2112474489 hasRelatedWork W1640140251 @default.
• W2112474489 hasRelatedWork W1993298608 @default.

• next